LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

Home・Aandelen Lijst・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Open

SectorGezondheidszorg

150.51 3.2

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

145.55

Max

153.06

Belangrijke statistieken
By Trading Economics
Inkomsten	-89M -454M
EPS	-2.29
Werknemers	883
EBITDA	-92M -441M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+20.2% upside

Dividenden
By Dow Jones
Volgende Winsten	5 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-750M 31B
Vorige openingsprijs	147.31
Vorige sluitingsprijs	150.51

Nieuwssentiment

By Acuity

50%

174 / 345 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

40.67 / 41.96 Steun & Weerstand

REVOLUTION Medicines Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 jan 2026, 11:10 UTC

Belangrijke Marktbewegers

Acquisities, Fusies, Overnames

Revolution Medicines Shares Slide Premarket After Merck Talks Cool

7 jan 2026, 20:13 UTC

Belangrijke Marktbewegers

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

17 okt 2025, 18:13 UTC

Belangrijke Marktbewegers

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

26 jan 2026, 09:55 UTC

Populaire aandelen

Stocks to Watch Monday: American Airlines, USA Rare Earth, RevMed -- WSJ

25 jan 2026, 19:30 UTC

Acquisities, Fusies, Overnames

Merck No Longer in Talks to Acquire Revolution Medicines, Sources Say -- WSJ

25 jan 2026, 19:30 UTC

Acquisities, Fusies, Overnames

Companies Had Been Discussing Roughly $30B Deal -- WSJ

25 jan 2026, 19:30 UTC

Acquisities, Fusies, Overnames

Merck No Longer in Talks to Buy Revolution Medicines -- WSJ

9 jan 2026, 19:58 UTC

Acquisities, Fusies, Overnames

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 jan 2026, 14:54 UTC

Acquisities, Fusies, Overnames

Revolution Medicines Stock Jumps. Takeover Buzz Grows, Another Suitor Emerges. -- Barrons.com

9 jan 2026, 10:54 UTC

Acquisities, Fusies, Overnames

Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges. -- Barrons.com

8 jan 2026, 14:49 UTC

Acquisities, Fusies, Overnames

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. -- Barrons.com

8 jan 2026, 12:38 UTC

Acquisities, Fusies, Overnames

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. -- Barrons.com

7 jan 2026, 22:43 UTC

Acquisities, Fusies, Overnames

Revolution Medicines Draws Takeover Interest -- 2nd Update

7 jan 2026, 20:29 UTC

Acquisities, Fusies, Overnames

AbbVie Near Deal for Revolution Medicines -- Update

7 jan 2026, 19:48 UTC

Acquisities, Fusies, Overnames

Revolution Has Market Value of Around $16B -- WSJ

7 jan 2026, 19:48 UTC

Acquisities, Fusies, Overnames

AbbVie Near Deal for Revolution Medicines -- WSJ

7 jan 2026, 19:48 UTC

Acquisities, Fusies, Overnames

Deal May Come Soon, Sources Say -- WSJ

7 jan 2026, 19:48 UTC

Acquisities, Fusies, Overnames

AbbVie in Advanced Talks to Buy Revolution Medicines, Sources Say -- WSJ

Peer Vergelijking

Prijswijziging

REVOLUTION Medicines Inc Prognose

Koersdoel

By TipRanks

20.2% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 177.05 USD 20.2%

Hoogste 263 USD

Laagste 140 USD

Gebaseerd op 20 Wall Street-analisten die 12-maands prijsdoelen bieden voor REVOLUTION Medicines Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

20 ratings

Buy

Hold

Sell

Gebaseerd op 20 analisten die aandelenratings hebben gegeven aan REVOLUTION Medicines Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

40.67 / 41.96Steun & Weerstand

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

174 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.